Garg Abhimanyu, Fazio Sergio, Duell P Barton, Baass Alexis, Udata Chandrasekhar, Joh Tenshang, Riel Tom, Sirota Marina, Dettling Danielle, Liang Hong, Garzone Pamela D, Gumbiner Barry, Wan Hong
Division of Nutrition and Metabolic Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas.
Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon.
J Endocr Soc. 2019 Nov 29;4(1):bvz015. doi: 10.1210/jendso/bvz015. eCollection 2020 Jan 1.
Familial hypercholesterolemia (FH) confers a very high risk of premature cardiovascular disease and is commonly caused by mutations in low-density lipoprotein receptor ( apolipoprotein B (), or proprotein convertase subtilisin/kexin type 9 () and very rarely in LDLR adaptor protein 1 () genes.
To determine the prevalence of pathogenic mutations in the , , and in a cohort of subjects who met Simon Broome criteria for FH and compare the clinical characteristics of mutation-positive and mutation-negative subjects.
Ninety-three men and 107 women aged 19 to 80 years from lipid clinics in the United States and Canada participated. Demographic and historical data were collected, physical examination performed, and serum lipids/lipoproteins analyzed. Targeted sequencing analyses of and coding regions and exon 26 of were performed followed by detection of deletions and duplications.
Disease-causing and variants were identified in 114 and 6 subjects, respectively. Of the 58 variants, 8 were novel mutations. Compared with mutation-positive subjects, mutation-negative subjects were older (mean 49 years vs 57 years, respectively) and had a higher proportion of African Americans (1% vs 12.5%), higher prevalence of hypertension (21% vs 46%), and higher serum triglycerides (median 86 mg/dL vs 122 mg/dL) levels.
mutations were the most common cause of heterozygous FH in this North American cohort. A strikingly high proportion of FH subjects (40%) lacked mutations in known culprit genes. Identification of underlying genetic and environmental factors in mutation-negative patients is important to further our understanding of the metabolic basis of FH and other forms of severe hypercholesterolemia.
家族性高胆固醇血症(FH)会带来极高的早发性心血管疾病风险,通常由低密度脂蛋白受体(LDLR)、载脂蛋白B(APOB)或枯草溶菌素/kexin 9型前蛋白转化酶(PCSK9)的突变引起,而LDLR衔接蛋白1(LDLRAP1)基因的突变则极为罕见。
确定符合西蒙·布鲁姆FH标准的一组受试者中LDLR、APOB和PCSK9致病突变的患病率,并比较突变阳性和突变阴性受试者的临床特征。
来自美国和加拿大脂质诊所的93名男性和107名年龄在19至80岁的女性参与了研究。收集了人口统计学和病史数据,进行了体格检查,并分析了血清脂质/脂蛋白。对LDLR和APOB的编码区以及PCSK9的第26外显子进行了靶向测序分析,随后检测了LDLRAP1的缺失和重复情况。
分别在114名和6名受试者中鉴定出致病的LDLR和PCSK9变异。在58个APOB变异中,有8个是新突变。与突变阳性受试者相比,突变阴性受试者年龄更大(平均分别为49岁和57岁),非裔美国人比例更高(1%对12.5%),高血压患病率更高(21%对46%),血清甘油三酯水平更高(中位数86mg/dL对122mg/dL)。
LDLR突变是该北美队列中杂合子FH最常见的原因。FH受试者中相当高比例(40%)在已知的致病基因中未发现突变。确定突变阴性患者潜在的遗传和环境因素对于加深我们对FH和其他严重高胆固醇血症形式的代谢基础的理解非常重要。